Hugh’s background includes 17 years in business development and licensing, including twelve years at Merck Life Science and two years in tech transfer at Cancer Research Technology
In the past two years Hugh’s role has involved the transacting of partnership agreements and licenses with University and Government counterparties for early-stage assets and platform technologies at BioNTech, a global leader in mRNA-based immunotherapies.